- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06530264
Evaluation of Different Methods of Posterior Flap Management in External Dacryocystorhinostomy
Evaluation of Different Methods of Posterior Flaps Management in External Dacryocystorhinostomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim of The Study
• To compare intraoperative details and postoperative endonasal endoscopic findings and their effects on success rate of external dacryocystorhinostomy with and without anastomosis of posterior mucosal flaps.
Patients and Methods
Study Design: This will be a prospective interventional comparative clinical study. It will include two groups according to the surgical procedure:- Group A: includes 30 eyes that will be treated with external DCR with anastomosis of posterior mucosal flaps .
Group B: includes 30 eyes that will be treated with external DCR with amputation of posterior mucosal flaps .
Study Population:
Study participants will be: 60 eyes undergo external DCR . All patients included in this study will be verbally briefed about the details and the nature of the study & will sign a written consent according to the local Ethics Committee of Minia University Faculty of Medicine. The study will be conducted in Ophthalmology department, Minia university Hospital, Egypt.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mohammed Sayed Abdelmaaboud, MD
- Phone Number: +20 01092503977
- Email: oph.msa1990@gmail.com
Study Contact Backup
- Name: Mohamed Farouk Sayed, Prof
- Phone Number: +20 01062555738
- Email: mohamed.osman@mu.edu.eg
Study Locations
-
-
-
Minya, Egypt, 61519
- Recruiting
- Faculty of medicine ,Minia university
-
Contact:
- Mohammed Sayed Abdelmaaboud, MD
- Phone Number: +20 01092503977
- Email: oph.msa1990@gmail.com
-
Contact:
- Mohamed Farouk Sayed, Prof
- Phone Number: +20 01062555738
- Email: mohamed.osman@mu.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria
- Patients with chronic dacryocystits,
- primary nasolacrimal duct obstruction
- Lacrimal mucocele
- Lacrimal fistula
Exclusion Criteria:
- Recurrent cases.
- Age under 5 years.
- Associated nasal pathology.
- Sever dry eye
- Patients unfit for general anaesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: External DCR
Different techniques in posterior flap management
|
6.
An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap.
Similarly an H shaped incision at the nasal mucosa is made.
The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Management of posterior flap in external DCR
Time Frame: patient evaluated at 2 months after surgery then at 4th month then 6th month
|
Evaluation of different methods of posterior flaps management in external dacryocystorhinostomy using nasal endoscopy for evaluation of outcomes
|
patient evaluated at 2 months after surgery then at 4th month then 6th month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Posterior flap managing in DCR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acquired Nasolacrimal Duct Obstruction
-
Menoufia UniversityCompletedPrimary Acquired Nasolacrimal Duct Obstruction
-
Western Galilee Hospital-NahariyaUnknownAcquired Nasolacrimal Duct ObstructionIsrael
-
National Taiwan University HospitalRecruitingPrimary Acquired Nasolacrimal Duct ObstructionTaiwan
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruitingPrimary Acquired Nasolacrimal Duct ObstructionChina
-
University of ArkansasRecruitingNasolacrimal Tract Obstruction | Nasolacrimal Duct ObstructionUnited States
-
Cairo UniversityUnknownCongenital Nasolacrimal Duct ObstructionEgypt
-
Tehran University of Medical SciencesUnknownCongenital Nasolacrimal Duct ObstructionIran, Islamic Republic of
-
Rutgers, The State University of New JerseyBausch & Lomb IncorporatedCompletedCongenital Nasolacrimal Duct ObstructionUnited States
-
Cathay General HospitalCompletedCongenital Nasolacrimal Duct ObstructionTaiwan
-
Mansoura UniversityNot yet recruitingPatient With Nasolacrimal Duct Obstruction | External Dacryocystorhinostomy OperationEgypt
Clinical Trials on DCR
-
Tehran University of Medical SciencesUnknownPrimary Acquired NasolacrimalIran, Islamic Republic of
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyParexelCompleted
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompletedHepatitis B, ChronicKorea, Republic of, New Zealand, Australia, Thailand, Hong Kong
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyTerminatedHepatocellular CarcinomaKorea, Republic of, United States, Singapore
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyTerminatedMultiple Myeloma | PNET | Solid Tumors | Non-Hodgkins Lymphoma | NHL | Pancreatic Neuroendocrine TumorsUnited States
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingEnd Stage Renal Disease | Primary Hyperoxaluria Type 1Germany, Spain, United States, Lebanon, United Kingdom, United Arab Emirates, France, Romania, Italy, Morocco
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompleted
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompletedPrimary Hyperoxaluria Type 3 | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1 | Primary HyperoxaluriaGermany, Italy, United Kingdom, Canada, Spain, United States, Japan, Lebanon, United Arab Emirates, Poland, Turkey (Türkiye)
-
University of AdelaideUniversity of Sydney; Salk Institute for Biological StudiesCompleted
-
Kafrelsheikh UniversityCompleted